Fosun Pharma Q1 2026 Report: Net Profit Attributable to Shareholders Excluding Non-recurring Items Increased by 21.96% YoY; Innovation Pipeline Progresses Efficiently

(April 28, 2026, Shanghai, China) On April 28, Fosun Pharma (600196.SH; $FOSUN PHARMA(2196.HK)) announced its first-quarter 2026 financial results. During the reporting period, the company achieved operating revenue of RMB 10.073 billion, a year-on-year increase of 6.93%. In terms of R&D investment, the company firmly implemented its innovation transformation strategy. R&D expenses for the period rose to RMB 897 million, an increase of RMB 159 million year-on-year. While increasing R&D intensity, the company's profit maintained a good growth trend. First-quarter net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was RMB 501 million, up 21.96% year-on-year. Net profit attributable to shareholders of the listed company was RMB 871 million, a 13.87% year-on-year increase. Net cash flow from operating activities was RMB 1.149 billion, up 8.8% year-on-year.

In the first quarter of 2026, guided by its strategy of "Innovation Leadership, Deep Internationalization, and Full Embrace of AI", Fosun Pharma steadfastly advanced its innovation transformation, synergistically promoting innovative R&D and international layout, further solidifying the foundation for high-quality development. Benefiting from continuous increases in R&D investment, the company's innovation achievements continued to materialize. During the reporting period, a total of 4 innovative drug marketing applications were accepted by China's NMPA or the U.S. FDA, and 14 (by number of approvals) innovative drug clinical trials were approved by domestic and international regulatory agencies, covering core therapeutic areas such as oncology. In the white paper "Pharma R&D Annual Review 2026" published by the globally renowned consulting firm Citeline, Fosun Pharma ranked among the top 20 globally, with its innovative R&D capabilities and pipeline quality receiving international professional recognition.

Deepening Core Technology Platforms, Strengthening Advantages in Oncology and Other Areas

Currently, Fosun Pharma has established an open R&D system integrating independent R&D, collaborative development, license-in, fund incubation, and industrial investment. It focuses on strengthening core technology platforms such as antibodies/ADCs, small molecules, and cell therapy, continuously consolidating its innovation moat in core therapeutic areas like oncology.

Regarding the antibody/ADC technology platform, the marketing and clinical progress of several biologics independently developed by Fosun Pharma's subsidiary, Henlius, is steadily advancing. Among them, Denosumab Injection (HLX14) was successfully approved for marketing in Canada in March 2026, covering all indications approved for the originator product locally, achieving a global commercial breakthrough in areas such as osteoporosis, bone metastases, and giant cell tumor of bone. The U.S. marketing application for Bevacizumab Injection (HLX04) was accepted, marking a new level in the company's international registration capabilities for biosimilars. The PD-L1-targeting antibody-drug conjugate HLX43 synergizes with HLX07 and Serplulimab, among others, for the treatment of solid tumors like advanced colorectal cancer, expanding precision treatment scenarios. HLX3901, a DLL3×DLL3×CD3×CD28 tetraspecific antibody, was approved for clinical trials, with multi-target synergy activating immune cells, showing good potential in refractory solid tumors.

Regarding the small molecule innovative drug platform, in January 2026, the marketing application for Fosun Pharma's Class 1 new drug Furutinib Succinate Capsules (SAF-189) was accepted by the NMPA, intended for ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), offering a potential new option for precision treatment of lung cancer. In February 2026, the marketing application for Fosun Pharma's self-developed MEK 1/2 inhibitor Luvomeitinib Tablets (domestic brand name: Fumaining) for the treatment of adult patients with type 1 neurofibromatosis (NF1) with symptomatic, inoperable plexiform neurofibromas (PN) was accepted by the NMPA and included in the priority review process. This marks a key step for this innovative drug towards covering patients of all ages, following its approval for pediatric and adolescent NF1 patients in May 2025, and brings new hope to the large number of adult NF1 patients in China lacking effective drug treatment. Additionally, the marketing application for the Class 1 new drug Etomidate Hydrochloride Injection (ET-26), developed by the holding subsidiary Aohong Pharma and intended for anesthesia induction and short-duration surgical anesthesia, was also accepted.

In early-stage pipeline forward-looking layout, several new molecules were approved for clinical trials. Among them, the PD-1-targeting IL-2 fusion protein FXB0871 was approved for clinical trials for locally advanced or metastatic solid tumors. Based on the ATTENUKINE™ technology platform, it holds promise for high efficacy and low toxicity. The next-generation Bcl-2 inhibitor FXS0683 was approved for Phase I clinical trials for hematologic malignancies. Innovative molecules such as HLX97 (KAT6A/B small molecule inhibitor) and HLX3901 (DLL3×DLL3×CD3×CD28 tetraspecific antibody) were successively approved for clinical trials, broadly covering refractory solid tumors such as breast cancer and small cell lung cancer. Furthermore, HLX22 (anti-HER2 monoclonal antibody) combined with HLX87 entered Phase II clinical trials for first-line treatment of HER2-positive recurrent or metastatic breast cancer. HLX43 (PD-L1 ADC) combined with HLX07 or Serplulimab Injection, HLX701 (CD47 fusion protein), etc., entered Phase I clinical trials, further solidifying the company's layout in the fields of tumor immunotherapy and targeted therapy.

Further Expansion of Global Commercialization Network and Continuous Enhancement of Academic Influence

During the reporting period, Fosun Pharma's global registration and commercialization network continued to expand. Overseas registration of products such as Denosumab and Bevacizumab progressed steadily, and deep collaborations were established with global partners like Eisai and Abbott, accelerating the coverage of innovative products in markets such as Japan, Asia-Pacific, the Middle East, Africa, and Eastern Europe.

In the academic field, the company's multiple innovation achievements were presented at top international academic conferences such as AACR and ASCO. Among them, Phase III study data for Luvomeitinib Tablets in treating adult patients with symptomatic, inoperable plexiform neurofibromas type I (NF1) were successfully selected for a Rapid Oral Abstract presentation at the 2026 ASCO Annual Meeting, with the research results to be first disclosed during the conference. At the 2026 American Association for Cancer Research (AACR) Annual Meeting, the holding subsidiary Henlius presented preclinical research data on the novel trispecific T-cell engager HLX3902 and the tetraspecific antibody HLX3901, demonstrating best-in-class therapeutic potential and laying a solid foundation for subsequent clinical development.

Fully Embracing AI and Driving Digital-Intelligent Transformation with FoSTRAID

Fosun Pharma continues to deepen its digital and AI strategic layout, systematically promoting the platformization, engineering, and scaled implementation of AI capabilities around core processes such as new drug R&D, clinical research, product services, and operations management. Building on this, the company has further clarified and advanced its comprehensive AI-embracing strategy centered on FoSTRAID (Fosun Pharma Strategic Transformation via AI & Data Science), constructing a digital-intelligent architecture with coordinated advancement of "Foundation-Platform-Data-Agents-Scenarios-Mechanisms" through resource integration.

Fosun Pharma's self-developed PharmAID pharmaceutical intelligence platform deeply utilizes large language models, fine-tuned for professional pharmaceutical corpora and R&D data. It has integrated decision-making tools for the entire process, including competitive product analysis, clinical competitiveness assessment, time-to-market prediction, and peak sales estimation, applied to key scenarios such as target discovery, molecular optimization, clinical writing, intelligence retrieval, and literature interpretation, aiming to provide systematic, data-driven support for drug R&D decision-making.

Looking ahead, Fosun Pharma will continue to adhere to the dual-engine drive of innovation and globalization, deepen core technology platforms, advance AI strategy implementation, accelerate pipeline conversion and global access, continuously provide high-quality pharmaceutical and healthcare products and services to patients worldwide, and strive to become a global leading integrated healthcare innovator.